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Many substances are active in in vitrotests for estrogenic activity, but data from multigenerational
and other toxicity studies are not available for many of those substances. Controversy has arisen,
therefore, concerning the likelihood of adverse health effects. Based on a toxic equivalence factor
risk assessment approach, some researchers have concluded that exposure to environmental
estrogens is not associated with estrogen receptor (ER)-mediated health effects. Their rationale
cites the low potency of these compounds in in vitro assays relative to estradiol, and the
widespread exposure to pharmaceutical, endogenous, and dietary estrogens. This reasoning
relies on two assumptions: that the relative estrogenic potency in in vitro assays is predictive of
the relative potency for the most sensitive in vivo estrogenic effect; and that all estrogens act via
the same mechanism to produce the most sensitive in vivo estrogenic effect. Experimental data
reviewed here suggest that these assumptions may be inappropriate because diversity in both
mechanism and effect exists forestrogenic compounds. Examples include variations in ER-ligand
binding to estrogen response elements, time course of nuclear ER accumulation, patterns of
gene activation, and other mechanistic characteristics that are not reflected in many in vitro
assays, but may have significance for ER-mediated in vivoeffects. In light of these data, this report
identifies emerging methodological issues in risk assessment for estrogenic compounds: the need
to address differences in in vivoend points of concern and the associated mechanisms; pharmaco-
kinetics; the crucial role of timing and duration of exposure; interactions; and non-ER-mediated
activities of estrogenic compounds. Environ Health Perspect 105(Suppl 3):655-663 (1997)
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Introduction
A number ofplant-derived and anthro-
pogenic compounds are now known to
have estrogenic activity (1-3). These com-
pounds include plant-derived dietary con-
stituents as well as plasticizers, surfactants,
constituents ofdetergents, pesticides, and
a variety of other chemicals (1,4-6).
Identification ofestrogenic activity is pri-
marily based on results of in vitro assays
that rely on indicators such as estrogen
receptor (ER) binding, gene transcription,
or cell proliferation, or on short-term
in vivo assays such as uterine growth
bioassays (7).
It is well known that estrogenic activity
may be observed due to direct effects ofa
compound binding the ER and inducing
gene transcription, and to indirect effects
such as induction ofenzymes involved in
metabolism or synthesis ofendogenous
estrogens (8,9), effects on binding ofendo-
genous estrogens to hormone binding pro-
teins (10), effects on ER regulation (11),
and others. Estrogenic compounds have also
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been reported to have other effects, such as
involvement in othercell signalingpathways
that may stimulate receptor-mediated estro-
gen action, e.g., protein kinase C (2,12,13),
inhibition ofmicrotubule polymerization
(14), or inhibition ofgap-junctional inter-
cellularcommunitation (GJIC) (15).
Exposure to estrogenic chemicals could
be substantial because oftheir widespread
use, yet data from sensitive in vivo studies
are not available for many of them.
Reproductive toxicity studies in animals are
typically required for pesticides and can
detect certain endocrine system effects;
however, many chemicals in common use
have not been screened for endocrine activ-
ity or examined in reproductive toxicity
studies. Data from multigenerational toxic-
ity studies in animals that allow identifica-
tion ofdevelopmental effects are available
for relatively few chemicals. Furthermore,
new protocols for conducting multigenera-
tional studies have identified more sensitive
endpoints forendocrine effects on develop-
ment than have been utilized in traditional
protocols (16-18).
Public concern about the potential
health effects ofexposure to environmental
pollutants with estrogenic activity, often
referred to as environmental estrogens, has
created pressure for scientists to make pre-
dictions about the significance ofcurrent
exposures to environmental estrogens in the
absence ofgood information on exposure,
effects, ordose response (19-21). Predicting
human health effects ofexposure to estro-
genic compounds involves synthesizing
assay information on the activities of a
broad spectrum ofestrogenic compounds to
which humans are simultaneously exposed,
including endogenous and pharmaceutical
estrogens, as well as phytoestrogens and
environmental estrogens. Many types of
compounds have been characterized as hav-
ing estrogenic activity; predicting health
effects associated with one class (environ-
mental estrogens) requires consideration of
the activities of, and interactions with, the
otherdasses ofestrogeniccompounds.
To date, predictions ofhuman health
effects ofexposure to these compounds
have covered awide range. Some researchers
have hypothesized that there may be an
association with serious health effects such
as breast cancer and fertility (3,22-25).
Others, however, have conduded that expo-
sure to environmental estrogens will not be
associated with any estrogen-mediated
adverse health effects in humans because of
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the low potency ofthose compounds in the
in vitro assays relative to endogenous estra-
diol, the high levels ofcirculating endoge-
nous estrogen, and the fact that so many
plant-derived estrogenic compounds are
present at high concentrations in food
(26). Although these factors are important
to consider in predicting the health effects
ofexposure to compounds with estrogenic
activity, the conclusion that environmental
estrogens will not be associated with adverse
health effects relies on several assumptions
that must be carefully examined (27).
Review of these assumptions brings into
focus a number ofconsiderations that an
empirically grounded risk assessment
methodology for estrogenic compounds
must address. These include the need to
address differences between estrogenic
compounds in in vivo end points of con-
cern and the associated mechanisms; the
impact ofpharmacokinetics on dose to tar-
get tissue and type of response observed;
the crucial role of timing and duration of
exposure in determining type and severity
ofresponse; the adequate consideration of
non-ER-mediated activities ofestrogenic
compounds; and the effects of mixtures,
including interactions between endogenous
hormones and substances that affect
endocrine function.
Toxic Equivalence Factors
for Risk Assessment
of Estrogenic Compounds
Because of the paucity ofcomprehensive
multigenerational toxicity studies for estro-
genic compounds, the conclusion that
exposure to environmental estrogens will
not be associated with adverse health
effects (26) relies on a toxic equivalence
factor (TEF) risk assessment based on
extrapolation from relative potency for ER-
mediated activity in in vitro screening
assays. The TEF risk assessment strategy
was developed as part ofthe risk assessment
for dioxin so that the in vivo toxic potency
for the dioxin congeners could be expressed
as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(2,3,7,8-TCDD) activity, based on relative
potency in producing enzyme induction in
in vitroassays (28).
In the case ofdioxin, use ofthe TEF
approach was predicated on the significant
finding that the chemical has to bind to a
receptor before causing any toxic effects
(29). In addition, manychronic studies had
been done to characterize the most sensitive
end points for 2,3,7,8-TCDD, and to
demonstrate similarity in mechanism and
effects of2,3,7,8-TCDD and other dioxin
congeners (28,29). Use of the TEF for
estrogenic activity relies similarly on two
assumptions: that the relative estrogenic
potency in in vitroassays for all compounds
is predictive ofthe relative potency for the
most sensitive in vivo estrogenic effect, and
that all estrogens act via the same mecha-
nism (e.g., binding ER) to produce the
most sensitive in vivoeffect.
One implication of making those
assumptions for estrogenic compounds is
the prediction that all estrogenic com-
pounds, like the dioxin congeners, have a
similar spectrum ofER-mediated effects
and so are essentially interchangeable. In
other words, diethylstilbestrol (DES),
genistein, 17P-estradiol, chlordecone,
nonylphenol, and other estrogenic com-
pounds (1) are assumed to induce similar
effects via the ER; and those effects are
assumed to represent the most sensitive
effects in vivo. These assumptions also
allow the prediction that a high dose ofa
weak estrogen is equivalent to a low dose of
a potent estrogen because, according to
the TEF rationale, the compounds would
differ from each other only in the dose
required to produce the effects.
This article highlights emerging
methodological issues in risk assessment for
estrogenic compounds. It presents experi-
mental data from in vitro and in vivo
studies that suggest that the TEF assump-
tions may not be appropriate for all estro-
genic compounds, and that additional in
vivo and in vitro data are needed before
such an approach can be applied with con-
fidence. In particular, it considers mecha-
nisms by which steroid receptors cause a
diverse spectrum ofeffects depending on
ligand, target tissue, timing ofdose, pres-
ence of other stimuli, and other factors
(30,31). It is possible that the factors
responsible for this diversity ofmechanism
and effect may be important in differenti-
ating the in vivo activities of estrogenic
compounds. These considerations also sug-
gest that the in vitro assays used to develop
relative potency estimates have not been
demonstrated to be representative of the
mechanism that will be important for
predicting the most sensitive in vivoeffects.
Experimental data presented here also
highlight examples in which timing or
duration ofdose, rather than simply size of
dose, determines the magnitude and type
of effect. The data also demonstrate the
impact ofpharmacokinetics on timing of
dose, and consequently the impact ofphar-
macokinetics on type of response, rather
than just size or duration of response.
These factors are also important to con-
sider when using a TEF approach to
extrapolate from in vitroto in vivoeffects.
In addition, manyestrogenic compounds
have multiple activities, both ER- and non-
ER mediated (above). Although most
chemicals have multiple mechanisms of
toxicity, these may be particularly impor-
tant to consider for estrogenic compounds
because activity at more than one point in
the steroid signaling system may not be
identified in in vitro studies but may have
profound implications in vivo.
Finally, although the question ofhow to
fashion risk assessment techniques to
address exposures to mixtures ofchemicals
has been discussed for some time, it may be
a particularly important component ofrisk
assessment for hormonally active com-
pounds. This is important so that interac-
tions between exogenous and endogenous
hormonally active compounds can be con-
sidered, and so that synergistic or antago-
nistic interactions between estrogenic/
antiestrogenic compounds can be addressed
(22), as well as those between compounds
with activity in more than one component
ofthe endocrine system, such as estrogens
and antiandrogens (32).
Diversity in Mechanisms and
Effects of Estrogenic
Compounds
The use of the TEF approach for risk
assessment for estrogenic compounds relies
on the assumption that all estrogens pro-
duce a similar spectrum ofER-mediated
responses for the most sensitive in vivo
effects and differ only in their potency rela-
tive to the reference compound. Exposure
to environmental or pharmaceutical estro-
gens or phytoestrogens is assumed to be an
extension ofthe exposure to endogenous
estrogens; all estrogens are assumed to
interact with the ER to increase or decrease
biological responses in the same way as
endogenous estrogens.
There are examples in the literature of
the induction ofsomewhat different effects
by different estrogenic compounds (30,31,
33-43). Although it is well known that
estrogenic compounds act on biological
materials in different ways and have multi-
ple effects, this information is reviewed here
because of its relevance to risk assessment
for these compounds. Specifically, these
reports illustrate some ofthe difficulties in
predicting in vivo health effects based on in
vitroscreening assays forestrogenic activity.
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For example, the phytoestrogen coume-
strol, a constituent ofsoy, has been estab-
lished as an estrogen in MCF-7 cells (1) and
immature rat uterus (33). In many assays,
coumestrol acts very much like a typical
estrogen. On the other hand, researchers
have reported that coumestrol in ovariec-
tomized rats behaved as an atypical estro-
gen. It has been known for many years that
coumestrol has mixed estrogen agonist and
antagonist activities (34,35). In more
recent experiments, it increased uterine wet
and dry weights but did not cause deple-
tion of cytosolic ER, accumulation of
nuclear ER, or uterine hyperplasia and
DNA synthesis, all characteristic estrogen
responses (36). Lack of uterine DNA syn-
thesis was observed in these experiments
even after multiple injections of coume-
strol, indicating that coumestrol was not
like estriol or other short-acting or weak
endogenous estrogens, which have been
shown to mimic more potent estrogens fol-
lowing chronic dosing. Whitten et al. (37)
investigated the influence ofdietary coume-
strol on estradiol action in the rat uterus
and found that coumestrol acted addi-
tively with estradiol for some end points
(increased uterine weight and decreased
cytosolic ER binding) in these experiments
but also dampened estradiol's induction of
progestin receptors, uterine protein, and
nuclear estrogen receptor binding (37).
Thus, in this system coumestrol's activities
do not appear to be identical to those of
estradiol, even after multiple doses; and
coumestrol modulates the activity of
endogenous estradiol.
In the male mouse treated neonatally
with DES, adult treatment with 17,-
estradiol induces prostatic metaplasia while
adult treatment with coumestrol or soy
does not induce metaplasia or prevent
173-estradiol-induced metaplasia (38).
Makela et al. refer to coumestrol as a par-
tial estrogen agonist in this system because
it weakly induced c-fos expression, though
estrogenic effects ofcoumestrol were gener-
ally missing in adult male neo-DES mice
(38). These researchers also found that
male mice fed a soy diet from fertilization
onward and neonatally treated with DES
had reduced dysplasia in the prostate com-
pared with mice not fed soy diets; this
effect was attributed to antiestrogenic
activity of soy (39). In summary, coume-
strol appears to be quite similar to 17p-
estradiol in some systems under some
conditions (e.g., MCF-7 cells, immature
rat uterus), but acts as an incomplete
estrogen or even modulates and dampens
the effects of endogenous estrogens in
other systems (male mouse, female rat).
These variations in activity cannot neces-
sarily be predicted from in vitro assays, but
mayhave implications for in vivoresponse.
In another study, the effect ofprenatal
exposure to genistein, also a component of
soy, was compared with that of DES and
estradiol in rats (40). All animals except
DES-treated females had smaller anogeni-
tal distance than controls. Genistein-
treated females had decreased volume of
sexually dimorphic nucleus in the preoptic
area of the hypothalamus (SDN-POA)
while DES and estradiol-treated females
had increased SDN-POA volume com-
pared to controls. In addition, genistein
had a unique effect in that it delayed
puberty onset. DES (but not estradiol or
genistein) increased the incidence ofatypi-
cal vaginal cycles (40). Thus genistein,
DES, and estradiol in this model induced
different effects. The researchers also noted
that the effects of prenatal and neonatal
exposure to genistein were inconsistent. In
previous experiments involving neonatal
exposure to genistein, castrated female rats
had decreased pituitary responsiveness to
gonadotropin-releasing hormone (GnRH)
and enlarged SDN-POAvolume. However,
prenatal genistein exposure in this experi-
ment did not affect pituitary responsive-
ness to GnRH and caused a nonsignificant
decrease in SDN-POAvolume (40).
Although very little research has been
done to compare activities ofendogenous
with environmental estrogens, one recent
study compared the effects oftwo environ-
mental estrogens, 4-tert-octylphenol (OP)
and methoxychlor, in immature female rats
(41). Both compounds accelerated vaginal
opening. Methoxychlor exposure increased
uterine weight but OP did not. In ovari-
ectomized rats, 17p-estradiol and methoxy-
chlor administered for 7 days induced
uterine growth, vaginal opening, and
elevated pituitary prolactin, while OP
induced vaginal opening but did not stim-
ulate uterine growth or pituitary prolactin
(41). Thus, OP appears to exhibit a differ-
ent spectrum ofestrogenic responses than
either estradiol or methoxychlor.
Although all the compounds discussed
in these examples ofvariation in effects of
estrogenic compounds were shown in the
respective studies to bind to the ER, and
most have been shown to induce cell pro-
liferation in MCF-7 cells (1), there are
many potential explanations for the differ-
ent effects observed. For example, different
pharmacokinetics, induction of enzymes
involved in endogenous estrogen synthesis
or metabolism, or other, unrelated effects
of test chemicals may have accounted for
the different responses observed. Timing of
dose during development also seems to be
an important modulator ofestrogen action.
These experiments involved complex phys-
iologic responses involving multiple recep-
tor-mediated processes, and sufficient data
are not available to characterize the mecha-
nisms responsible for the differences.
However, the major point to note is that
differences in responses to estrogenic com-
pounds occur that could not be predicted
by the TEF risk assessment approach that
relies on relative in vitro potencies for a
single effect.
Much more information is available on
differences between activities ofendogenous
and pharmaceutical estrogens, such as DES.
These experiments provide insight and sup-
port for the idea that different ER ligands
may produce different patterns of ER-
associated gene activation. A recent paper by
Stancel et al. (31) discusses their hypothesis
and that ofothers indicating that different
estrogens may exhibit selective patterns in
the activation ofestrogen-responsive genes.
These researchers report that the estrogen
response element (ERE) for different genes
varies in sequence and in location relative to
the gene (31). They suggest that the EREs
ofdifferent genes may be selectively or dif-
ferentially activated by different ER-ligand
complexes, and this may be responsible for
the differential response patterns produced
bydifferent estrogens.
In support ofthis hypothesis, Stancel et
al. (31) review a number of reports that
suggest differential activation of EREs by
different estrogens. Korach et al. (42) found
that DES and a series of DES analogs, all
ofwhich bound to the mouse uterine ER
with high affinity and caused nuclear ER
retention and occupancy similar to that of
estradiol, differed in their ability to induce
responses such as induction of uterine
DNA synthesis and stimulation of uterine
glucose 6-phosphate dehydrogenase. These
researchers speculate that the chemical
nature ofthe ligand-receptor complex may
influence its activity at different genetic
sites. In addition, VanderKuur et al. (43)
found that the relationship between ER
binding affinity, nudear binding ofthe ER
complex, and induction ofprogesterone
receptor was not consistent for a series of
estradiol analogs examined.
Stancel et al. (31) discuss the toxicolog-
ical implications ofthis proposed paradigm
with respect to environmental and other
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estrogens, noting that different conforma-
tions ofligand-ER could activate or repress
genes differently than endogenous hor-
mone and thus produce an imbalanced
estrogenic response. For example, consider
the possibility that estradiol produces
hypothetical gene products A, B, and C in
a 1:1:1 concentration ratio and another
estrogen produces only products A and B
and produces them in a ratio of 1:2.
Because the signal from the two estrogens
differs, it is possible that disruption ofcell
function could result that is not predicted
by the effect ofa slightly increased dose of
estradiol, which in this hypothetical exam-
ple would be expected to produce slightly
more ofA, B, and C in a 1:1:1 ratio. Thus,
some estrogens could produce a state of
estrogenization that is qualitatively differ-
ent from that produced by endogenous
hormone (rather than simply a quantitative
extension ofestradiol) and that perhaps
cannot be compensated for by homeostatic
mechanisms (31).
The examples cited here illustrate the
difficulty ofpredicting the specific in vivo
estrogen-related activities of compounds
identified as estrogenic in screening assays.
The many mechanisms by which steroid
receptors bind a diverse set ofligands and
produce an even more diverse spectrum of
responses has been discussed by Fuller
(30), who reviewed mechanisms by which
specificity and diversity are generated at
each step in the fundamental process of
gene regulation by steroid receptors.
Because these various mechanisms ofcreat-
ing diverse responses to signals involving a
set ofsimilar steroid hormone receptors are
likely to be active in modulating the effects
ofvarious estrogenic ligands (above), they
need to be considered in predicting the
effects ofexposure on human health.
Can Screening Assays
Help Predict in Vivo
No-Effect Levels?
Although these examples demonstrate that
it is difficult to predict in vivo estrogenic
effects at doses that are high enough to
produce effects, it is worth considering
whether relative potency in in vitro or
short-term in vivo screening assays for ER-
mediated activity could be useful in identi-
fying a threshold dose, or no-effect level,
for the activity ofestrogenic compounds. A
number of issues that would be important
to address are briefly mentioned here. First,
it would be necessary to identify the most
sensitive in vivo effect and the conditions
in which an in vitro test should be done to
ensure that the relevant mechanism is cap-
tured. In other words, the normal parame-
ters ofthe steroid signaling system in vivo,
at critically sensitive times, would have to
be understood, so that predictions could be
made as to what level of perturbation to
that signaling system would have no
adverse effect. In evaluating whether a par-
ticular exposure to an ER ligand would
result in binding and any subsequent
effect, one would have to consider the
many in vivo factors that would impact the
ability ofthe ligand in question to bind the
ER. Such factors might include sensitivity
oftarget tissue, presence ofanother ligand,
amount ofreceptor available, serum bind-
ing proteins, and others. Second, the recent
reports ofstriking synergistic effects ofmul-
tiple ER ligands applied as mixtures (22)
suggest other important factors involved in
regulating ER activity that need to be
explored before the activity of a single lig-
and in an in vitro screening assay provides
a basis for predicting in vivo estrogenic
effects or lack ofthem.
In addition, consider the hypothesis of
Stancel and others (31) that ERligands vary
in the specific pattern ofgenes activated.
The in vivo end point associated with a test
compound that activates one set of genes
may be different from that expected from
17p-estradiol. Because the TEF approach is
useful only when the most sensitive in vivo
effect is similar for the test and reference
compounds, it would no longer be valid to
compare the potency of test compounds
with the potency ofestradiol. Furthermore,
the in vitroassay inwhich relative potency is
established would have to represent a mech-
anism relevant to the in vivo effect ofcon-
cern, which in this hypothetical example
would be a pattern ofgene activation related
to the end point ofconcern caused by the
testchemical, notbyestradiol.
Finally, biological systems closely regu-
late steroid hormone and receptor levels
through multiple and complex mechanisms
(30). Endogenous estrogens have multiple
activities in this signaling system, so it is
not surprising that the structural character-
istics of some compounds that bind ER
may also result in those compounds being
active in other estrogen-sensitive processes,
such as inhibition ofenzymes involved in
synthesis ofendogenous estrogen (8). Most
sensitive effects in vivo may occur due to
compounds acting by multiple mechanisms
in approximately the same dose range.
The in vivo significance of these multiple
activities is difficult to predict based on the
study ofone end point, such as ERbinding.
For example, polychlorinated biphenyls
(PCBs) not only mimic thyroid hormones
but may also bind thyroid hormone recep-
tors in the pituitary, thus blocking thyroid-
stimulating hormone release and inhibiting
a mechanism that would compensate for
reduced hormone levels (44). It is well
known that different estrogenic compounds
act through different mechanisms and pro-
duce multiple and varied effects. We are
reviewing this information here because it
needs to be considered when predicting in
vivo health effects based on extrapolation
from screening tests for estrogenic activity.
ER Dynamics: Nuclear
Accumulation and Impact
of Pharmacokinetics
The time course ofnuclear accumulation of
the ER-ligand complex has been studied in
the context ofefforts to understand mecha-
nisms ofestrogen-induced responses such as
uterine hyperplasia (45-49). Generally,
researchers using a mouse or rat uterine
assay have shown a biphasic increase in
nuclear ER levels to follow treatment with
17p-estradiol or DES. Increase in uterine
wet weight follows the time course ofthe
biphasic nuclear ER increase, with only the
second phase described as "true uterine
growth" due to increased cellular DNAsyn-
thesis. The first increase in nuclear ER
accumulation and uterine weight is shown
1 to 3 hr after dose, and the second increase
7 to 9 hr after dose. Weak estrogens show
the early response phase only, although
multiple doses of some weak endogenous
estrogens mimic the effect of more potent
estrogens (7). Nuclear ER levels return
to approximately control levels about
10 hr after treatment with estradiol (46).
Cytosolic ER levels decrease as nuclear ER
levels increase and ultimately increase above
control levels (36,46).
Limited work has been done in these
model systems to examine the time course
of ER nuclear accumulation following
treatment with a variety of estrogens.
Katzenellenbogen et al. (50) evaluated
temporal relationships between estrogen
receptor binding and uterine growth for
DES and stilbestrol derivatives. These
researchers and others noted that increased
retention of nuclear receptors correlated
with prolonged elevation of uterine weight
and stimulation ofdeoxyglucose metabo-
lism, or true uterine growth. The impor-
tant role of pharmacokinetic factors in
modulating the estrogenic effect of a weak
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estrogen is apparent from their study. The
weak estrogen dimethylstilbestrol (DMS)
and its dimethylether DMS-(OMe)2,
which does not bind ER, were tested in the
assay. Acting like a typical weak estrogen,
DMS induced short-term but not long-
term nuclear accumulation ofER and uter-
ine growth. The DMS-(OMe)2, which had
to be metabolically activated to the weakly
estrogenic DMS, induced long-term
increases in nuclear ER and uterine growth
because metabolic activation proceeded at a
rate that simulated chronic dosing (50).
Repeated dosing with some weak estrogens
can cause long-term increases in uterine
growth such as those caused by more
potent estrogens (above). Thus, the phar-
macokinetics ofestrogens can modify not
only the duration ofa response, but also
the type ofestrogenic response observed.
Patterns ofER localization after treat-
ment with coumestrol in similar assays
shows some conflicting but interesting dif-
ferences from ERlocalization after estradiol,
estriol, or DES treatment. WhileWhitten et
al. (33) found that coumestrol in the diet of
immature rats increased nuclear ER concen-
trations, Markaverich et al. (36) reported
that coumestrol failed to cause substantial
nuclear accumulation of ER in ovariec-
tomized rats, although it did cause increase
in uterine wet and dryweights. Markaverich
et al. (36) show a slight increase in nuclear
ER after coumestrol treatment, with levels
returning to control levels in less than 5 hr
and then decreasing slightly below control
levels through 24 hr. Treatment with a
higher dose ofcoumestrol did not modify
this pattern or increase nuclear ER, indi-
cating that coumestrol was not able to
function as a more potent estrogen in this
system. Estradiol stimulation, on the other
hand, caused a significant increase in
nuclear ER that returned to control levels
by 5 hr after treatment. Coumestrol
appeared to induce long-term increases in
cytosolic ER, which increased slowly but
continuously over the 24 hr during which
measurements were made.
In an experiment looking at coumestrol
modulation ofestradiol action in the rat
uterus, Whitten et al. (37) found that ani-
mals that received coumestrol along with
physiologic doses ofestradiol for 90 hr had
lower levels of nuclear ER than controls.
When these animals were challenged with
a single estradiol dose, the coumestrol-
treated animals produced a smaller increase
in nuclear ERthan controls (37). Although
there is conflicting evidence about whether
coumestrol alone substantially increases
nuclear ER (33,36), it does appear that a
coumestrol diet diminished the nuclear ER
accumulation after estradiol treatment
(37). In another example ofthe differential
abilities of various estrogens to induce
nuclear accumulation, Martin et al. (51)
reported that in MCF-7 cells, genistein and
coumestrol (both soy derivatives) were less
effective at translocating ER to the nucleus
than zearalenol (a mycotoxin) andestradiol.
Hammond et al. (52) reported that the
organochlorine pesticide chlordecone is
estrogenic and interacts with rat uterine
estrogen receptors. In experiments compar-
ing estradiol and chlordecone, nuclear ER
levels increased quickly following estradiol
treatment and then decreased to nearly
control levels by 12 hr posttreatment.
Chlordecone, on the other hand, increased
nuclear ER slowly, reaching maximum at
36 hr and maintaining that level through
the end of the experiment at 48 hr. The
long half-life of chlordecone, therefore,
appears to moderate the relative potency of
the compound in vivo, but may also mod-
erate the qualitative estrogenic effect due to
the potential importance ofthe time course
of ER-ligand activity in the nucleus in
determining the nature of the estrogenic
response. For example, pharmacokinetics
ofthe ER-ligand complex could affect the
length of time that expression of some
genes remain elevated (31).
In another example of how different
estrogens exhibit different pharmacokinet-
ics with respect to nuclear accumulation of
ER, administration ofo,p'-DDT to imma-
ture female rats caused translocation ofER
to the nucleus that was maximal 3 hr after
treatment; estradiol in this system caused
maximal nuclear ER 1 hr after treatment
(53). In experiments comparing the time
course of uterine weight increases in rats
following treatment with amsonic acid and
DES, both test compounds induced an
extended increase relative to estriol (6).
Amsonic acid is an optical brightening
agent that was tested for estrogenic activity
after reports of sexual impotence among
exposed factoryworkers (6).
It has been observed that the duration
of nuclear ER accumulation affects the
response observed, although this relation-
ship has been explored only for a few
endogenous and pharmaceutical estrogens
(45-50). The fact that certain phytoestro-
gens and environmental estrogens show
variation in timing ofnudear ER accumu-
lation (33,36,37,52,53) strongly suggest
that it may be important to consider timing
and duration of dosing in determining
effect. This is important because it is not
clear that the effects ofincreasing the dura-
tion ofnuclear accumulation ofactivated
ER are equivalent to the effects ofsimply
increasing the dose ofestradiol. Pharmaco-
kinetic considerations are also important,
therefore, in determining not only dose
to target tissue, but potentially also in
characterizing the end point expected.
Consideration of Effects
on Estrogen Synthesis,
Metabolism, and
Bioavailability
Because estrogen synthesis and metabolism
in vivo are regulated by many factors
including endogenous estrogen, it is not
surprising that exogenous estrogens often
also affect these regulatory mechanisms
(8,23). In attempting to predict health
effects of exposure to xenobiotic com-
pounds, it is important to consider the abil-
ity ofa compound to alter the endogenous
hormone environment by influencing syn-
thesis or metabolism ofendogenous estro-
gens (and other endogenous steroids). Of
course, these effects involve mechanisms
that do not necessarily involve binding ER.
Some compounds cause changes in levels
of cytochrome P450 enzymes that are
involved in estrogen metabolism (indirect
estrogenic effects) (9,23,54), while other
compounds that induce ER-mediated gene
transcription also affect synthesis or
metabolism ofestradiol (8). Effects on the
endogenous hormone environment cannot
be accounted for by assuming that the con-
sequences ofexposure to exogenous estro-
gens are simply an extension ofexposure to
endogenous hormone, because the effects
on hormone synthesis and metabolism vary
among estrogenic compounds. Although it
is not surprising that any compounds have
multiple effects, consideration ofmultiple
effects for estrogenic compounds may be
particularly important because ofthe result-
ingdifficulty ofpredicting interference with
normal signalingprocesses.
For example, Bradlow et al. (23) have
shown that exposure to a number ofcom-
pounds, many ofwhich are estrogenic, can
affect the metabolism of 17p-estradiol by
shifting the ratio of two metabolites, 2-
hydroxyestrone and 16a-hydroxyestrone.
This effect may be important for predict-
ing health effects because the 16a-hydroxy
metabolite is genotoxic and a potent estro-
gen, while the 2-hydroxyestrone metabolite
is not reported to be genotoxic and is only
very weakly estrogenic (55). Others have
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reported that the plant-derived flavonoid
quercetin, which increases the severity of
estradiol-induced tumorigenesis in hamster
kidney, operates by increasing the forma-
tion of the catechol estradiol metabolite
4-hydroxyestradiol, which may undergo
redoxcycling and generate free radicals (54).
Makela et al. (8) reported that several
plant estrogens, including coumestrol and
genistein, reduce the conversion ofestrone
to 17p-estradiol by inhibiting the estrogen-
specific enzyme 17p-hydroxysteroid oxido-
reductase Type 1 in vitro, but zearalenone
and DES did not inhibit this enzyme.
Thus, the phytoestrogens coumestrol and
genistein, which have been reported by
some as incomplete estrogens incapable of
inducing all the effects of 170-estradiol
(36,40), may also decrease availability of
active endogenous estrogen by inhibiting its
synthesis. These types ofdifferences in the
combination of ER-mediated and other
estrogen-related effects ofexogenous com-
pounds may have significant impacts on
their potential health effects.
Differences in the bioavailability of
compounds in vivo and effects ofestrogenic
compounds on the bioavailability of
endogenous estrogens are additional factors
that will modulate toxicity in vivo. These
factors should also be considered in predic-
tions ofhealth effects ofexposure to these
compounds. One of the most important
modulators of the availability ofendoge-
nous estrogens may be the serum-binding
proteins like sex hormone-binding globulin
(SHBG). While this protein can modulate
the availability ofendogenous estrogens, in
most cases its ability to modulate the avail-
ability ofexogenous estrogens remains to be
explored. SHBG appears not to bind many
environmental estrogens (16,56), but estro-
genic compounds may affect SHBG bind-
ing to endogenous estrogens (57). This
observation offers another mechanism by
which exogenous estrogens may modulate
endogenous estrogen activity.
The importance ofthe steroid hormone
microenvironment within cells has been
recognized and mechanisms ofregulation
of enzymes involved in estrogen metabo-
lism and synthesis are being explored at the
level of the target tissue (58-61). The
effects ofxenobiotics on systemic estrogen
regulation may be different from their
effects on estrogen regulation in the target
tissue. For example, the cytochrome P450
enzymes that are inducible by different
xenobiotics vary among tissues, which
means that a compound may have different
effects on endogenous estrogen metabolism
in the liver and the breast, for example
(61-64). Thus, it is important to consider
the questions ofsynthesis, metabolism, and
bioavailability at the level of the cell and
target tissue, as well as at the systemic level.
Of course, pharmacokinetics are also
important in determining dose to target
tissue. Concentrations oflipophilic chemi-
cals in mammary adipose tissue, for exam-
ple, may be much higher than serum
concentrations, and exposure presented as
body burden is often substantially different
from exposure presented as daily intake
due to pharmacokinetic considerations.
Other Effects of Estrogens
and Effects of Mixtures
Environmental estrogens present a special
challenge for risk assessment because they
have the potential to be active in many dif-
ferent ways. Effects at multiple points in a
signaling system in vivo may be difficult to
predict from in vitro or short-term in vivo
tests, as demonstrated for PCBs and
thyroid hormones, discussed earlier (44).
In addition, researchers have reported
the ability ofDES, some stilbene estrogens,
and the common environmental estrogen
bisphenol-A, to inhibit microtubule forma-
tion (14). Endogenous estrogens and phy-
toestrogens tested in this cell-free assay did
not have that effect. Inhibition ofmicro-
tubules in intact cells may lead to the
induction ofmicronuclei and aneuploidy,
which may play a role in estrogen-mediated
carcinogenesis (14).
The idea that estrogens may regulate
cellular function at sites other than specific
gene-regulating receptors has been explored
recently (13,65). Plasma membrane-
resident forms ofER have been proposed to
explain observations ofcellular responses to
estrogen that occur within minutes and so
cannot be explained through gene transcrip-
tion (65). In addition, other researchers
have shown that chemicals-that activate pep-
tide growth factor signaling systems, such as
protein kinase-C activators, can also induce
ERE-dependent transcription (12). These
researchers showed that a protein kinase-C
activator acted synergistically with 173-
estradiol to induce ERE-dependent tran-
scription. They also showed that epidermal
growth factor, which produces estrogen-
like effects in the mouse reproductive tract,
increases levels of nuclear ER (12). These
researchers note that the potential health
effects associated with exposure to exoge-
nous estrogens may also be observed follow-
ing exposure to chemicals that could activate
peptide growth factor signaling systems.
Recently researchers showed that dield-
rin, DDT, and toxaphene, all ofwhich have
been reported to be estrogenic, inhibited
GJIC in normal human breast epitheliel
cells in a dose responsive manner. Effects of
these compounds were additive, with sub-
threshold doses ofindividual compounds
being effective when combined (15). Many
tumor promotors have the ability to inhibit
GJIC. It is hypothesized that inhibition
of GJIC may release initiated cells from
suppressing effects ofsignals passing from
surrounding normal cells (15).
The effects ofmixtures ofcompounds
may be particularly striking for estrogenic
and other hormonally active compounds,
and thus particularly important for risk
assessment. As illustrated above, certain
phytoestrogens modulate the activity of
endogenous estrogens (37). In addition,
recent reports of synergistic activity of
some environmental estrogens in vitro
[(22); A Soto, personal communication],
as well as information on the presence of
environmental and dietary antiestrogens
(26,66), suggest that interactions could
be important.
Screening and exposure characterization
needs to be comprehensive enough to iden-
tify all kinds of biological activity (67).
Although o,p'-DDT was reported to be
estrogenic before 1970 (68), the potent
antiandrogenic activity ofp,p'-DDE was
not reported until 1995 (32). In addition,
because activity ofestrogen is also modu-
lated by other hormones, such as proges-
terone (69), it is important that these
biological activities are considered in a
comprehensive manner.
Conclusions
The challenge ofpredicting health effects of
exposures to estrogenic compounds is
daunting because ofthe current limitations
in our understanding. Chemicals have not
been routinely screened for these endocrine
activities before being introduced to com-
merce, and so the significance ofcurrent
levels ofexposure to environmental estro-
gens, or other hormonally active com-
pounds, is unclear. In addition, data from
multigenerational or other sensitive toxicity
studies are not available for most com-
pounds to provide information on hazard
identification and dose response. The goal
ofthis artide is to suggest that it is simplis-
tic to generalize that the effects ofall estro-
genic compounds can be predicted by
assuming that their in vivo effects will nec-
essarily be extensions of the effects of
170-estradiol, based on a screening test for
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estrogenic activity. Screening tests are useful
to identify compounds for further study,
but must be used with caution to predict
health effects or no-effect levels. Although it
is not clear whether current levels ofexpo-
sure to estrogenic or other hormonally
active compounds in the environment are
associated with health effects, it is prema-
ture to dismiss exposure to environmental
estrogens as a concern for human health
effects based on relative in vitropotency.
A substantial body ofexperimental data
provides insight into differences among
estrogenic compounds in terms of mecha-
nisms ofaction and end points. For exam-
ple, data suggest variations between
compounds in ER-ligand binding to EREs
(31), time course ofnuclear ER accumula-
tion (36,52), patterns ofgene activation
(38), and other mechanistic characteristics.
These and other data presented here suggest
that the assumption that relative potency in
in vitro screening assays is representative of
relative potency for the most sensitive ER-
mediated in vivo effect has not been
demonstrated to be accurate.
Current toxicity testing protocols may
not be adequate to identify endocrine
effects, and may need to be expanded to
accommodate the special challenges ofrisk
assessment for estrogenic compounds. For
example, for some estrogen-mediated end
points the dose response curve is such that
high-dose experiments are not likely to be
predictive of low dose effects (16,56).
Therefore, it may be necessary to broaden
testing protocols to look at an extended
dose-response curve. It may also be
appropriate to modify protocols to evaluate
an enlarged spectrum ofend points, includ-
ing more sensitive end points like delayed
developmental or behavioral effects. For
example, Vom Saal et al. (16) found terri-
torial behavior in male mice affected by
prenatal exposure to 0.001 mg/day ofDES
or 1 mg/day of o,p'-DDT; and Chapin et
al. (17) have developed new protocols for
testing a variety ofendocrine, immune, and
neurological effects ofcertain pesticides.
It is well known that timing of expo-
sure has a substantial impact on the dose
required to induce an effect. Testing proto-
cols need to identify the most sensitive
periods for exposure and to follow up for
latency and multigenerational effects. In
addition, timing ofexposure can affect the
type of response observed. For example,
neonatal exposure of rats to genistein
produced an enlarged SDN-POA, while
prenatal exposure decreased SDN-POA
volume (40). Duration ofdosing also has
an important impact on patterns ofnuclear
accumulation of ER and resulting effects
(50), so pharmacokinetics and dosing
regimes have an impact on the qualitative
as well as quantitative nature of the
response. Thus, consideration oftime as a
third axis on the dose-response curve may
be particularly important for endocrine
effects. The time axis could incorporate
information on when in the lifecycle of
the organism exposure occurs, as well as
duration of exposure of the target tissue.
The experimental data reviewed in this
paper provide examples ofthe importance
of both these fa4tors in determining the
toxicological end points observed.
Risk assessment for estrogenic com-
pounds must consider, among other fac-
tors, the diversity in effects observed
between classes ofestrogens in various ani-
mal models, the importance ofpharmaco-
kinetics, timing, and duration ofexposure
in modulating the spectrum oftoxicologi-
cal end points, the diverse (ER- and non-
ER-mediated) activities ofmany estrogenic
compounds, and the interactions between
multiple compounds to which individuals
are simultaneously exposed, including
interactions between exogenous and endo-
genous factors. Emerging questions about
risk assessment techniques for hormonally
active compounds, therefore, may require
new methods.
We propose that a focused research
strategy be developed to investigate the
mechanisms ofaction, diversity ofeffects,
and pharmacokinetics of endocrine dis-
rupters. This research should integrate the
study of endogenous, synthetic, anthro-
pogenic, and phytoestrogens in a focused
program that will not only increase our
understanding ofpotential health effects
associated with exposure to these com-
pounds in diet and the environment, but
will provide insight into the role of
endogenous hormones in breast cancer and
other major health concerns.
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